FibroGenesis cell therapy product could treat COVID-19 fibrosis

By The Science Advisory Board staff writers

July 21, 2020 -- FibroGenesis has released new preclinical data regarding its PneumoBlast cell therapy product for reducing lung injury associated with COVID-19 in preparation for an investigational new drug submission to the U.S. Food and Drug Administration (FDA).

PneumoBlast is comprised of proprietary "universal donor" fibroblasts for the treatment of acute respiratory distress syndrome (ARDS), a contributing symptom of severe COVID-19. The company has demonstrated that the product reduces lung fibrosis by as much as 51% in a bleomycin model of lung scarring.

In comparison to bone marrow derived mesenchymal stem cells for the treatment of COVID-19, PneumoBlast was 221% more effective. The product produces a potent anti-inflammatory protein interleukin 1 receptor antagonist, which helps prevent scar tissue, according to the company. Scar tissue formation, or fibrosis, is a common post-COVID-19 symptom and has been reported in COVID-19 patients in their 20s and 30s.

Constant Therapeutics to begin phase II trial for COVID-19 therapy
Constant Therapeutics' peptide drug TXA127 will advance to phase II clinical trials for the treatment of hospitalized COVID-19 patients.
Viscient to bioprint lung tissues to accelerate COVID-19 research
Biotherapeutics company Viscient Biosciences said it, or a sister company to be funded and launched shortly using the same technology, will use 3D bioprinting...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter